CV			
Name Degree	Luis Miguel Bedoya PhD.	**Title (current position)**	Associate Professor of Pharmacology

Education			
Institution / Location	**Degree**	**Year**	**Field of Study**
Pharmacy college, UCM/ Madrid, Spain	**Pharmacist graduate**	**1998**	
Pharmacology Department. Pharmacy college, UCM/ Madrid, Spain	**PhD. student**	**1998-2003**	**Pharmacology of natural products**
AIDS Immunopathology Department, CNM, ISCIII/Majadahonda, Spain	**PhD. researcher**	**2005-**	**Virology and pharmacology**
Pharmacology Department, Pharmacy College, UCM/Madrid, Spain	**Associate professor**	**2007-**	**Pharmacology, antivirals**

Positions

Associate Researcher. AIDS Immunopathology Department, CNM, ISCIII/Majadahonda, Spain.

Associate Professor. Pharmacology Department, Pharmacy College, UCM/Madrid, Spain.

Selected Peer-Reviewed Publications last 5 years

Structure-based design of an RNA-binding p-terphenylene scaffold that inhibits HIV-1 Rev protein function. González-Bulnes L, Ibáñez I, Bedoya LM, Beltrán M, Catalán S, Alcamí J, Fustero S, Gallego J. Angew Chem Int Ed Engl. 2013 Dec 9;52(50):13405-9.

3-Phenylcoumarins as inhibitors of HIV-1 replication. Olmedo D, Sancho R, Bedoya LM, López-Pérez JL, Del Olmo E, Muñoz E, Alcamí J, Gupta MP, San Feliciano A. Molecules. 2012 Aug 2;17(8):9245-57.

Olean-18-ene triterpenoids from Celastraceae species inhibit HIV replication targeting NF-kB and Sp1 dependent transcription. Osorio AA, Muñóz A, Torres-Romero D, Bedoya LM, Perestelo NR, Jiménez IA, Alcamí J, Bazzocchi IL. Eur J Med Chem. 2012 Jun;52:295-303.

The artemisia L. Genus: a review of bioactive essential oils. Abad MJ, Bedoya LM, Apaza L, Bermejo P. Molecules. 2012 Mar 2;17(3):2542-66.

Quinoline-based compounds as modulators of HIV transcription through NF-kappaB and Sp1 inhibition. Bedoya LM, Abad MJ, Calonge E, Saavedra LA, Gutierrez C M, Kouznetsov VV, Alcami J, Bermejo P. Antiviral Res. 2010 Sep;87(3):338-44.

Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents. Di Gianvincenzo P, Marradi M, Martínez-Avila OM, Bedoya LM, Alcamí J, Penadés S. Bioorg Med Chem Lett. 2010 May 1;20(9):2718-21.

An update on drug interactions with the herbal medicine Ginkgo biloba. Abad MJ, Bedoya LM, Bermejo P. Curr Drug Metab. 2010 Feb;11(2):171-81.

Ellagitannins from Tuberaria lignosa as entry inhibitors of HIV. Bedoya LM, Abad MJ, Sánchez-Palomino S, Alcami J, Bermejo P. Phytomedicine. 2010 Jan;17(1):69-74.

Multivalent manno-glyconanoparticles inhibit DC-SIGN-mediated HIV-1 trans-infection of human T cells. Martínez-Avila O, Bedoya LM, Marradi M, Clavel C, Alcamí J, Penadés S. Chembiochem. 2009 Jul 20;10(11):1806-9.

Anti-infectious activity in the Cistaceae family in the Iberian Peninsula. Bedoya LM, Bermejo P, Abad MJ. Mini Rev Med Chem. 2009 May;9(5):519-25.

SJ23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vitro. Bedoya LM, Márquez N, Martínez N, Gutiérrez-Eisman S, Alvarez A, Calzado MA, Rojas JM, Appendino G, Muñoz E, Alcamí J. Biochem Pharmacol. 2009 Mar 15;77(6):965-7.

Biographical sketch

My research activity is focused on drug discovery through new compounds screening obtained from different sources, as natural compounds, chemistry and biotechnology, and to study their mechanism of action. Our group has identified new anti-HIV compounds with novel targets and use them as tools to understand the viral replication cycle in the molecular and cellular levels. Currently, microbicide development and anti-latency compounds identification are the main goals of our group. In addition, since 2007, I teach pharmacology related subjects in Universidad Complutense de Madrid.

Mi actividad investigadora actual se centra en la búsqueda de nuevos antiretrovirales mediante cribado de compuestos de origen natural, químico o biotecnológico y el estudio de su mecanismo de acción. Hemos identificado nuevos compuestos con actividad anti-VIH a través de nuevas dianas y hemos utilizado estos nuevos compuestos como herramientas para comprender como funciona el ciclo de infección viral a nivel molecular y celular. El desarrollo de nuevos microbicidas y la identificación de reactivadores de latencia son actualmente los objetivos principales del grupo. Por otro lado, desde de 2007, desarrollo también actividad docente en el Departamento de Farmacología en la Universidad Complutense de Madrid.